Kry Dexrazoxane Market Players:
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V. (now part of Viatris)
- Hikma Pharmaceuticals PLC
- Fresenius Kabi AG
- Sun Pharmaceutical Industries Ltd.
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd.
- Sandoz International GmbH (Novartis division)
- Accord Healthcare Inc.
- Gland Pharma Ltd.
- Jiangsu Aosaikang Pharm Co., Ltd.
- Intas Pharmaceuticals Ltd.
- Apotex Inc.
- Baxter International Inc.
- Nippon Kayaku Co., Ltd.
- Sawai Pharmaceutical Co., Ltd.
- Kyowa Kirin Co., Ltd.
- Nichi-Iko Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited
Companies involved in the market are witnessing intensifying competition between the global players in various regions. Leading firms such as Pfizer Inc. and Hikma Pharmaceuticals are gaining exceptional recognition with products such as Zinecard and Totect. Besides, companies in developing countries are enhancing manufacturing capabilities to meet the rising demand. Furthermore, firms are leveraging collaborations, regulatory support, and research investments to enhance their product portfolio. Hence, with these constant efforts from the players across all nations, the market will grow at the fastest rate.
Below is the list of some prominent players in the industry:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In 2026, the industry size of dexrazoxane is estimated at USD 935.6 million.
Dexrazoxane market size was valued at USD 887.7 million in 2025 and is projected to reach USD 1502 million by the end of 2035, rising at a CAGR of 5.4% during the forecast period, i.e., 2026 to 2035.
The North America dexrazoxane market is poised to capture the largest share of 40.5% during the forecast period, 2026-2035.
The major players in the market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V. (now part of Viatris), Hikma Pharmaceuticals PLC, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Sandoz International GmbH (Novartis division), Accord Healthcare Inc., Gland Pharma Ltd., Jiangsu Aosaikang Pharm Co., Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Baxter International Inc., Nippon Kayaku Co., Ltd., Sawai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited.
